| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 22 | |
| #2 | United States | 16 | |
| #3 | Canada | 8 | |
| #4 | Australia | 5 | |
| #5 | EPO (European Patent Office) | 5 | |
| #6 | China | 4 | |
| #7 | Republic of Korea | 4 | |
| #8 | Singapore | 3 | |
| #9 | Israel | 2 | |
| #10 | Mexico | 2 | |
| #11 | Brazil | 1 | |
| #12 | Philippines | 1 | |
| #13 | Taiwan | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Organic fine chemistry | |
| #3 | Audio-visual technology | |
| #4 | Biotechnology | |
| #5 | Civil engineering | |
| #6 | Mechanical elements |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Heterocyclic compounds | |
| #3 | Medical preparations | |
| #4 | Casings and printed circuits | |
| #5 | Microorganisms | |
| #6 | Peptides | |
| #7 | Structural elements | |
| #8 | General building constructions | |
| #9 | Shafts |
| # | Name | Total Patents |
|---|---|---|
| #1 | Marx Matthew Arnold | 38 |
| #2 | Christensen James Gail | 36 |
| #3 | Savechenkov Pavel | 18 |
| #4 | Chicarelli Mark Joseph | 15 |
| #5 | Fell Jay Bradford | 15 |
| #6 | Vigers Guy P A | 15 |
| #7 | Marx Matthew | 14 |
| #8 | Mejia Macedonio J | 14 |
| #9 | Blake James F | 14 |
| #10 | Fischer John P | 14 |
| Publication | Filing date | Title |
|---|---|---|
| US2021085683A1 | Combination therapies | |
| US2021078994A1 | MTA-Cooperative PRMT5 Inhibitors | |
| WO2021050580A1 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | |
| WO2021041671A1 | Kras g12d inhibitors | |
| WO2020247475A1 | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer | |
| WO2020219448A1 | Naphthyridine derivatives as prc2 inhibitors | |
| WO2020167952A1 | Mat2a inhibitors | |
| WO2020146613A1 | Kras g12c inhibitors | |
| CA3112129A1 | Combination therapies | |
| CA3111980A1 | Combination therapies | |
| WO2020055758A1 | Combination therapies | |
| WO2020055760A1 | Combination therapies | |
| AU2019340366A1 | Combination therapies | |
| WO2020055755A1 | Combination therapies | |
| WO2020047192A1 | Kras g12c inhibitors | |
| US2019270743A1 | KRas G12C inhibitors | |
| WO2019217307A1 | Kras g12c inhibitors | |
| CN112004816A | PRC2 inhibitors | |
| KR20200100632A | KRAS G12C inhibitor | |
| US2018265517A1 | EZH2 inhibitors |